{"id":"sitagliptin-plus-metformin","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Muscle pain"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1201174","moleculeType":"Small molecule","molecularWeight":"523.33"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Sitagliptin works by inhibiting the enzyme DPP-4, which breaks down incretin hormones. This leads to an increase in incretin levels, which in turn stimulates the release of insulin from the pancreas. Metformin, on the other hand, decreases the production of glucose in the liver and increases the body's sensitivity to insulin, making it easier for glucose to enter the cells.","oneSentence":"Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin levels, enhancing glucose-dependent insulin secretion, and metformin, a biguanide, decreases hepatic glucose production and increases insulin sensitivity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:34:51.585Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"},{"name":"Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06246799","phase":"PHASE3","title":"Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-11-07","conditions":"Type 2 Diabetes (Adult Onset)","enrollment":256},{"nctId":"NCT07452913","phase":"PHASE4","title":"Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes","status":"ENROLLING_BY_INVITATION","sponsor":"Bahria University","startDate":"2026-01-01","conditions":"Type 2 Diabetes Mellitus","enrollment":110},{"nctId":"NCT05042505","phase":"NA","title":"Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation","status":"COMPLETED","sponsor":"Medanta, The Medicity, India","startDate":"2022-01-01","conditions":"Diabetes Mellitus, Liver Transplant; Complications","enrollment":100},{"nctId":"NCT06851962","phase":"PHASE4","title":"Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2025-05-26","conditions":"Diabetes Mellitus Type 2","enrollment":504},{"nctId":"NCT07374328","phase":"PHASE1, PHASE2","title":"Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2025-06-01","conditions":"Type 2 Diabetes","enrollment":240},{"nctId":"NCT07365358","phase":"PHASE4","title":"Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients","status":"NOT_YET_RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2026-03","conditions":"Diabete Type 2","enrollment":200},{"nctId":"NCT06560333","phase":"PHASE3","title":"iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD)","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-11-30","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT05367063","phase":"PHASE4","title":"Canagliflozin and Myocardial Fibrosis","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-01-05","conditions":"Type 2 Diabetes, Cardiovascular Risk","enrollment":45},{"nctId":"NCT06759922","phase":"PHASE4","title":"Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes","status":"COMPLETED","sponsor":"Bahria University","startDate":"2025-01-01","conditions":"Type 2 Diabetes Mellitus","enrollment":172},{"nctId":"NCT01471808","phase":"PHASE4","title":"Effects of Different Early Intensive Therapies on Long-term β-cell Function","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2011-10","conditions":"Diabetes Mellitus, Type 2","enrollment":264},{"nctId":"NCT07172269","phase":"NA","title":"Mangosteen Supplement as Adjuvant Therapy With Sitagliptin/Metformin in Iraqi Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Mais Qais Hbeeb","startDate":"2024-09-15","conditions":"Diabete Mellitus, Type 2 Diabetes, Obesity Type 2 Diabetes Mellitus","enrollment":58},{"nctId":"NCT06972732","phase":"PHASE4","title":"A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2025-06-11","conditions":"Type 2 Diabetes","enrollment":204},{"nctId":"NCT07076056","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2","status":"COMPLETED","sponsor":"Daewon Pharmaceutical Co., Ltd.","startDate":"2022-10-27","conditions":"Type 2 Diabetes","enrollment":230},{"nctId":"NCT02879409","phase":"NA","title":"HbA1c Variability in Type II Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2016-11","conditions":"Diabetes Mellitus Type 2","enrollment":150},{"nctId":"NCT06952231","phase":"PHASE3","title":"Effect of Sitagliptin and Empagliflozin in Combination With Metformin on Hs-CRP Levels in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Lahore","startDate":"2024-05-21","conditions":"Diabetes Mellitus","enrollment":50},{"nctId":"NCT06875193","phase":"PHASE4","title":"DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes","status":"RECRUITING","sponsor":"Dong Wha Pharmaceutical Co. Ltd.","startDate":"2024-05-28","conditions":"Type2diabetes","enrollment":196},{"nctId":"NCT04409795","phase":"PHASE2, PHASE3","title":"Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study","status":"COMPLETED","sponsor":"Joslin Diabetes Center","startDate":"2021-08-26","conditions":"Type 1 Diabetes, Monogenic Diabetes","enrollment":3},{"nctId":"NCT02512523","phase":"PHASE4","title":"Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study)","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2015-08-27","conditions":"Type 2 Diabetes Mellitus","enrollment":39},{"nctId":"NCT02452632","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2015-06-22","conditions":"Type 2 Diabetes Mellitus","enrollment":143},{"nctId":"NCT04017832","phase":"PHASE3","title":"A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-07-29","conditions":"Diabetes Mellitus, Type 2","enrollment":1441},{"nctId":"NCT06613750","phase":"PHASE4","title":"Comparative Study of Sitagliptin and Gliclazide With Metformin in Type 2 Diabetes Patients With Glucotoxicity","status":"COMPLETED","sponsor":"Zhibin Xu","startDate":"2024-06-01","conditions":"Type 2 Diabetes Mellitus, Glucotoxicity","enrollment":129},{"nctId":"NCT05833958","phase":"PHASE2","title":"Polypill Versus Metformin in New Onset Type 2 Diabetes","status":"WITHDRAWN","sponsor":"George Medicines PTY Limited","startDate":"2024-09","conditions":"Type 2 Diabetes","enrollment":""},{"nctId":"NCT04017221","phase":"","title":"Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-10-01","conditions":"Diabetes Mellitus, Type 2, Urosepsis, Diabetic Ketoacidosis","enrollment":1249636},{"nctId":"NCT06570980","phase":"","title":"Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.","status":"RECRUITING","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-08-25","conditions":"Type 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin","enrollment":200},{"nctId":"NCT06515652","phase":"NA","title":"To Compare the Effects of Herbal Medicines With Traditional Allopathic Medicines in Cases of Patients With Metabolic Syndrome","status":"RECRUITING","sponsor":"Hamdard University","startDate":"2023-09-01","conditions":"Metabolic Syndrome","enrollment":200},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT03918148","phase":"","title":"Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2018-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":1150},{"nctId":"NCT06147518","phase":"NA","title":"To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2023-12-20","conditions":"Compensated Cirrhosis, Decompensated Cirrhosis","enrollment":240},{"nctId":"NCT06124495","phase":"PHASE1","title":"Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.","status":"COMPLETED","sponsor":"Galenicum Health","startDate":"2023-01-13","conditions":"Bioequivalence, Diabetes Mellitus, Type 2","enrollment":58},{"nctId":"NCT06124547","phase":"PHASE1","title":"Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.","status":"COMPLETED","sponsor":"Galenicum Health","startDate":"2023-01-16","conditions":"Bioequivalence, Diabetes Mellitus, Type 2","enrollment":48},{"nctId":"NCT06124560","phase":"PHASE1","title":"Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.","status":"COMPLETED","sponsor":"Galenicum Health","startDate":"2022-10-28","conditions":"Bioequivalence, Diabetes Mellitus, Type 2","enrollment":58},{"nctId":"NCT06124573","phase":"PHASE1","title":"Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.","status":"COMPLETED","sponsor":"Galenicum Health","startDate":"2022-11-07","conditions":"Bioequivalence, Diabetes Mellitus, Type 2","enrollment":48},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":550000},{"nctId":"NCT05822674","phase":"","title":"Variable Effects of Anti-diabetics on Stress Hyperglycemia Ratio","status":"COMPLETED","sponsor":"University of Diyala","startDate":"2022-01-01","conditions":"Type 2 Diabetes","enrollment":80},{"nctId":"NCT05798715","phase":"PHASE1","title":"Bioequivalence Study of of Metformin HCl From Gleptomet 50/1000 mg F.C.Tablets (EVA Pharma, Egypt) and Janumet 50/1000 mg F.C.Tablets (Merck Sharp & Dohme, The Netherlands)","status":"COMPLETED","sponsor":"Genuine Research Center, Egypt","startDate":"2022-11-29","conditions":"Healthy","enrollment":30},{"nctId":"NCT02244164","phase":"NA","title":"Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.","status":"TERMINATED","sponsor":"Erasme University Hospital","startDate":"2014-10","conditions":"Type 2 Diabetes, Incretinomimetics, Pancreas","enrollment":5},{"nctId":"NCT03076112","phase":"PHASE3","title":"Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2017-04-25","conditions":"Type 2 Diabetes Mellitus","enrollment":170},{"nctId":"NCT01485614","phase":"PHASE3","title":"Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02-10","conditions":"Diabetes Mellitus, Type 2 Diabetes","enrollment":200},{"nctId":"NCT01760447","phase":"PHASE3","title":"A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-12-07","conditions":"Type 2 Diabetes Mellitus","enrollment":223},{"nctId":"NCT05549570","phase":"PHASE1","title":"Comparative Bioavailability Study of Metformin/Sitagliptin 850 mg/50 mg Tablets in Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"Galenicum Health","startDate":"2017-10-22","conditions":"Bioequivalence, Diabetes Mellitus, Type 2","enrollment":26},{"nctId":"NCT05549583","phase":"PHASE1","title":"Comparative Bioavailability Study of Sitagliptin/Metformin 50 mg/1000 mg Tablets in Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"Galenicum Health","startDate":"2018-04-15","conditions":"Bioequivalence, Type 2 Diabetes","enrollment":26},{"nctId":"NCT01131182","phase":"PHASE4","title":"Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-13","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":1147},{"nctId":"NCT05480007","phase":"NA","title":"Non-alcoholic Fatty Liver Disease and Its Treatment","status":"COMPLETED","sponsor":"Shanghai 10th People's Hospital","startDate":"2011-01-30","conditions":"NAFLD","enrollment":68},{"nctId":"NCT05347459","phase":"","title":"Cognitive Protective Effect of Newer Antidiabetic Drugs","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2022-03-02","conditions":"Type 2 Diabetes","enrollment":100},{"nctId":"NCT05386186","phase":"PHASE4","title":"The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-01-01","conditions":"Diabetes Mellitus, Type 2, Severe Insulin Deficient Diabetes","enrollment":192},{"nctId":"NCT05167513","phase":"PHASE4","title":"Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Getz Pharma","startDate":"2021-01-01","conditions":"Quality of Life, Type 2 Diabetes, Metformin+Sitagliptin","enrollment":188},{"nctId":"NCT05359341","phase":"NA","title":"Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?","status":"COMPLETED","sponsor":"Sadat City University","startDate":"2020-09-20","conditions":"Diabete Type 2","enrollment":175},{"nctId":"NCT02623998","phase":"PHASE3","title":"Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita)","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2016-07-09","conditions":"Type 2 Diabetes Mellitus","enrollment":102},{"nctId":"NCT03659461","phase":"NA","title":"Glucagon-like Peptide-1 Levels, Insulin Resistance and Insulin Sensitivity Index in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"National University of Malaysia","startDate":"2017-10-01","conditions":"Type 2 Diabetes Mellitus, PreDiabetes","enrollment":174},{"nctId":"NCT02338921","phase":"PHASE4","title":"Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2015-01","conditions":"Type 2 Diabetes","enrollment":78},{"nctId":"NCT02250794","phase":"PHASE4","title":"Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2014-10","conditions":"Type 2 Diabetes Mellitus","enrollment":""},{"nctId":"NCT05032001","phase":"NA","title":"ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT","status":"UNKNOWN","sponsor":"Metabolic Research Unit","startDate":"2021-08-01","conditions":"Abdominal Obesity, Type 2 Diabetes","enrollment":30},{"nctId":"NCT05035849","phase":"NA","title":"Comparison of the FGM Profiles in Patients of Type 2 Diabetes Treated With Sitagliptin and Acarbose","status":"COMPLETED","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2020-01-30","conditions":"Type 2 Diabetes","enrollment":60},{"nctId":"NCT02956044","phase":"PHASE1","title":"Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin","status":"COMPLETED","sponsor":"Theracos","startDate":"2016-11","conditions":"Type2 Diabetes Mellitus","enrollment":54},{"nctId":"NCT03115112","phase":"PHASE3","title":"Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Theracos","startDate":"2017-10-12","conditions":"Type 2 Diabetes Mellitus","enrollment":386},{"nctId":"NCT04916093","phase":"PHASE4","title":"Safety and Efficacy of Antidiabetic Drugs in Recently Diagnosed Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2019-12-20","conditions":"Diabetes Mellitus, Type 2","enrollment":60},{"nctId":"NCT02653209","phase":"PHASE4","title":"TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Royal Devon and Exeter NHS Foundation Trust","startDate":"2016-11-01","conditions":"Type 2 Diabetes","enrollment":525},{"nctId":"NCT02315287","phase":"PHASE4","title":"Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-09","conditions":"Type 2 Diabetes","enrollment":190},{"nctId":"NCT04268563","phase":"PHASE1, PHASE2","title":"Comparing the Effect of Sitagliptin/Metformin and Metformin in PCOS Patients","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-01-10","conditions":"Polycystic Ovary Syndrome, Infertility, ART","enrollment":80},{"nctId":"NCT04192292","phase":"NA","title":"Study of Sulphonylurea Synergy With DPP4 Inhibitors","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2019-10-08","conditions":"Type 2 Diabetes","enrollment":30},{"nctId":"NCT03061214","phase":"PHASE3","title":"Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-08-28","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":868},{"nctId":"NCT03359590","phase":"PHASE2","title":"Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Profil Institut für Stoffwechselforschung GmbH","startDate":"2018-03-21","conditions":"Pharmacological Action","enrollment":20},{"nctId":"NCT00860288","phase":"PHASE2, PHASE3","title":"Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-02","conditions":"Diabetes Mellitus, Type 2","enrollment":1988},{"nctId":"NCT01557504","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-18","conditions":"Type 2 Diabetes Mellitus","enrollment":25},{"nctId":"NCT04298684","phase":"PHASE4","title":"Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules in Type 2 Diabetes","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de la Guadeloupe","startDate":"2021-01-01","conditions":"Diabetes Mellitus, Type 2, Thyroid Nodule (Benign)","enrollment":90},{"nctId":"NCT02043054","phase":"PHASE3","title":"Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2013-12-16","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Disease","enrollment":90},{"nctId":"NCT01140438","phase":"NA","title":"Treatment of Latent Autoimmune Diabetes of the Adult","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2009-03","conditions":"Diabetes","enrollment":64},{"nctId":"NCT03267576","phase":"PHASE4","title":"An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-10-27","conditions":"Diabetes Mellitus, Type 2","enrollment":64},{"nctId":"NCT02072096","phase":"PHASE4","title":"A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-02","conditions":"Diabetes Mellitus, Type 2","enrollment":192},{"nctId":"NCT02111096","phase":"PHASE2","title":"A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-04","conditions":"Diabetes Mellitus, Type 2","enrollment":174},{"nctId":"NCT03813316","phase":"PHASE4","title":"Approaches To Therapy Escalation In T2D","status":"WITHDRAWN","sponsor":"LMC Diabetes & Endocrinology Ltd.","startDate":"2019-05-01","conditions":"Type2 Diabetes","enrollment":""},{"nctId":"NCT01930188","phase":"PHASE3","title":"Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-12-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1231},{"nctId":"NCT02060383","phase":"PHASE4","title":"Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-05-23","conditions":"Cushing's Disease, Acromegaly","enrollment":249},{"nctId":"NCT01999218","phase":"PHASE3","title":"Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-16","conditions":"Type 2 Diabetes Mellitus","enrollment":1326},{"nctId":"NCT01336322","phase":"PHASE2","title":"Metformin and Sitagliptin in Women With Previous Gestational Diabetes","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2011-05","conditions":"Pre-diabetes","enrollment":40},{"nctId":"NCT02188186","phase":"PHASE4","title":"Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-07","conditions":"Type 2 Diabetes","enrollment":200},{"nctId":"NCT02791490","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-06-16","conditions":"Type 2 Diabetes Mellitus","enrollment":458},{"nctId":"NCT02373865","phase":"PHASE4","title":"Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"GWT-TUD GmbH","startDate":"2015-09","conditions":"Diabetes Mellitus Type 2","enrollment":4},{"nctId":"NCT02647320","phase":"PHASE2","title":"12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2016-01","conditions":"Type 2 Diabetes Mellitus","enrollment":298},{"nctId":"NCT02738879","phase":"PHASE3","title":"Randomized Sitagliptin Withdrawal Study (MK-0431-845)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-05-09","conditions":"Type 2 Diabetes Mellitus","enrollment":746},{"nctId":"NCT02256189","phase":"PHASE4","title":"Sitagliptin and Glucagon Counterregulation","status":"COMPLETED","sponsor":"Lund University","startDate":"2015-04","conditions":"Type 2 Diabetes","enrollment":28},{"nctId":"NCT02532855","phase":"PHASE3","title":"A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-20","conditions":"Type 2 Diabetes Mellitus","enrollment":614},{"nctId":"NCT01907854","phase":"PHASE4","title":"Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-12-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":407},{"nctId":"NCT01059825","phase":"PHASE2","title":"Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-02-24","conditions":"Diabetes Mellitus, Type 2","enrollment":375},{"nctId":"NCT02036515","phase":"PHASE3","title":"Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-12","conditions":"Type 2 Diabetes Mellitus","enrollment":464},{"nctId":"NCT02099110","phase":"PHASE3","title":"Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-04-22","conditions":"Type 2 Diabetes Mellitus","enrollment":1233},{"nctId":"NCT01841697","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-06-13","conditions":"Type 2 Diabetes","enrollment":642},{"nctId":"NCT01702298","phase":"PHASE3","title":"A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-07","conditions":"Type 2 Diabetes Mellitus","enrollment":42},{"nctId":"NCT01678820","phase":"PHASE3","title":"A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-10","conditions":"Type 2 Diabetes Mellitus","enrollment":299},{"nctId":"NCT00993187","phase":"PHASE4","title":"Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05-04","conditions":"Type 2 Diabetes Mellitus","enrollment":292},{"nctId":"NCT01545388","phase":"PHASE3","title":"Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02-23","conditions":"Type 2 Diabetes Mellitus","enrollment":337},{"nctId":"NCT01709305","phase":"PHASE4","title":"A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-11-08","conditions":"Type 2 Diabetes Mellitus","enrollment":5570},{"nctId":"NCT01590771","phase":"PHASE3","title":"A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-09","conditions":"Type 2 Diabetes Mellitus","enrollment":498},{"nctId":"NCT01462266","phase":"PHASE3","title":"Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-01-13","conditions":"Type 2 Diabetes Mellitus","enrollment":660},{"nctId":"NCT01590797","phase":"PHASE3","title":"A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-10","conditions":"Type 2 Diabetes Mellitus","enrollment":467},{"nctId":"NCT02365233","phase":"PHASE4","title":"Fatty Liver Study in Patients With Type II Diabetes","status":"TERMINATED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2013-05-01","conditions":"Type II Diabetes, Nonalcoholic Fatty Liver","enrollment":5},{"nctId":"NCT01477853","phase":"PHASE3","title":"A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":166},{"nctId":"NCT03593135","phase":"NA","title":"Effect of Apple Cider Vinegar in Type 2 Diabetics","status":"COMPLETED","sponsor":"Sheikh Zayed Federal Postgraduate Medical Institute","startDate":"2017-07-15","conditions":"Randomized Controlled Trial, Diabetes Mellitus","enrollment":126},{"nctId":"NCT02284893","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09-09","conditions":"Type 2 Diabetes","enrollment":461},{"nctId":"NCT02147925","phase":"PHASE4","title":"Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2014-08","conditions":"Non-alcoholic Fatty Liver Disease","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MK-0431A","MK-0431A XR"],"phase":"phase_3","status":"active","brandName":"Sitagliptin plus metformin","genericName":"Sitagliptin plus metformin","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sitagliptin, a dipeptidyl peptidase IV inhibitor, is used in combination with metformin to treat Type 2 Diabetes. This combination is classified as a small molecule inhibitor of the Dipeptidyl peptidase 4 enzyme.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}